Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 3/2016

01-09-2016 | Case Report

Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide

Authors: Adrian Tempescul, Jean-Christophe Ianotto, Cristina Bagacean, Pierre-Yves Salaun, Corina Bocsan, Mihnea Zdrenghea

Published in: International Journal of Hematology | Issue 3/2016

Login to get access

Abstract

Mantle cell lymphoma is a hematologic malignancy characterized by poor therapeutic outcomes. Immunomodulatory drugs are a focus of attention in this disease, especially for the elderly and frail patients not able to tolerate the typically intensive therapeutic approaches used in fitter patients. We here present the case of refractory mantle cell lymphoma of the elderly that achieved complete remission following the use of single-agent lenalidomide, and a second complete response to the same regimen on relapse 5 years later.
Literature
1.
Swerdlow SH. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: WHO Press; 2008.
2.
3.
Tempescul A, Ianotto JC, Morel F, Marion V, De Braekeleer M, Berthou C. Lenalidomide, as a single agent, induces complete remission in a refractory mantle cell lymphoma. Ann Hematol. 2009;88(9):921–2.CrossRefPubMed
4.
Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90(8):739–45.CrossRefPubMed
5.
Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, et al. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012;91(11):1765–72.CrossRefPubMed
6.
Mussetti A, Kumar A, Dahi PB, Perales MA, Sauter CS. Lifting the mantle: unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev. 2015;29(3):143–52.CrossRefPubMed
7.
Avivi I, Goy A. Refining the mantle cell lymphoma paradigm: impact of novel therapies on current practice. Clin Cancer Res. 2015;21(17):3853–61.CrossRefPubMed
8.
9.
Kritharis A, Coyle M, Sharma J, Evens AM. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities. Blood. 2015;125(16):2471–6.CrossRefPubMedPubMedCentral
10.
Habermann TM, Lossos IS, Justice G, Vose JM, Wiernik PH, McBride K, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol. 2009;145(3):344–9.CrossRefPubMed
11.
Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22(7):1622–7.CrossRefPubMed
12.
Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–95.CrossRefPubMedPubMedCentral
Metadata
Title
Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide
Authors
Adrian Tempescul
Jean-Christophe Ianotto
Cristina Bagacean
Pierre-Yves Salaun
Corina Bocsan
Mihnea Zdrenghea
Publication date
01-09-2016
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 3/2016
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-016-2020-4

Other articles of this Issue 3/2016

International Journal of Hematology 3/2016 Go to the issue

Erratum

Erratum to: Regulation of hematopoietic development by ZBTB transcription factors

Case Report

Long-term survival of donor bone marrow multipotent mesenchymal stromal cells implanted into the periosteum of patients with allogeneic graft failure

Progress in Hematology

Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs

Original Article

Causes of macrocytic anemia among 628 patients: mean corpuscular volumes of 114 and 130 fL as critical markers for categorization

Progress in Hematology

Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma

Review Article

Regulation of hematopoietic development by ZBTB transcription factors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits